Sirolimus albumin bound - Abraxis Bioscience

Drug Profile

Sirolimus albumin bound - Abraxis Bioscience

Alternative Names: ABI-009; Nab-rapamycin; Nab-sirolimus

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abraxis BioScience
  • Developer AADi; Children's Oncology Group; National Cancer Institute (USA)
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Perivascular epithelioid cell tumours
  • Phase I/II Bladder cancer; Sarcoma
  • Phase I Pulmonary arterial hypertension; Solid tumours

Most Recent Events

  • 19 Mar 2018 AADi plans a phase II trial for Glioma (Late-stage disease, Recurrent, Second-line therapy or greater) and Glioblastoma (Newly diagnosed) in June 2018 (NCT03463265)
  • 20 Feb 2018 AADi plans a phase I/II trial for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) (NCT03439462)
  • 24 Aug 2017 Phase-I/II clinical trials in Sarcoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03190174)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top